RISK OF ADENOCARCINOMA IN BARRETT'S ESOPHAGUS

Authors:

Abstract:

The total of 7396 videoesophagogastroscopy cases were analyzed. The presence of metaplastic columnar epithelium of esophagus was found in 2910 patients (39.4%) at pathohistological examination. The gastric metaplasia was evaluated in 876 cases (11.9%), the specialized intestinal metaplasia without dysplasia - in 1970 (26.6%), the low-grade dysplasia - in 48 (0.65%), the high-grade dysplasia - in 16 (0.22%). Esophageal adenocarcinoma was evaluated in four patients (0.05%, CI 0.01 - 0.12%). Low probability of esophageal adenocarcinoma formation in all types of metaplasia was demonstrated. Оnly the presence of dysplasia of metaplastic epithelium should cause increased alertness for the occurrence of esophageal adenocarcinoma. Exaggerated value of Barrett’s esophagus may result in additional traumatization of mucosa, increase the risk of bleeding and stenosis.

Keywords:

Barrett's esophagus metaplasia dysplasia esophageal adenocarcinoma

References:

1. Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, Murray LJ. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011; 103(13): 1049-57. https://doi.org/10.1093/jnci/djr203
2. Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, Howden CW. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut. 2012; 61(7): 970-6. https://doi.org/10.1136/gutjnl-2011-300730
3. Erichsen R, Horvath-Puho E, Lund JL, Dellon ES, ShaheenNJ, Pedersen L, Davey Smith G, Sorensen HT. Mortality and cardiovascular diseases risk in patients with Barrett’s oesophagus: a population-based nationwide cohort study. Aliment Pharmacol Ther. 2017; 45(7): 973-982. https://doi.org/10.1111/apt.13962
4. Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014; 63(1): 7-42. https://doi.org/10.1136/gutjnl-2013-305372
5. Holmberg D, Ness-Jensen E, Mattsson F, El-Serag H.B., Lagergren J. Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus. Eur J Cancer. 2017; 75: 41-46. https://doi.org/10.1016/j.ejca.2016.12.037
6. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011; 365(15): 1375-83. https://doi.org/10.1056/NEJMoa1103042
7. Kahrilas PJ. The problems with surveillance of Barrett’s esophagus. N Engl J Med. 2011; 365(15): 1437-8. https://doi.org/10.1056/NEJMe1108435.
8. Kestens C, Leenders M, Offerhaus GJ, van Baal JW, Siersema PD. Risk of neoplastic progression in Barrett’s esophagus diagnosed as indefinite for dysplasia: A nationwide cohort study. Endoscopy. 2015; 47: 409–414. https://doi.org/10.1055/s-0034-1391091
9. Liu S, Dai JY, Yao L, Li X, Reid B, Self S et al. Esophageal Adenocarcinoma and Its Rare Association with Barrett's Esophagus in Henan, China. PLoSOne. 2015; 10(4): e0127135. https://doi.org/10.1371/journal.pone.0110348
10. Ma M, Shroff S, Feldman M, DeMarshall M, Price C, Tierney A, Falk GW. Risk of malignant progression in Barrett’s esophagus indefinite for dysplasia. Dis. Esophagus. 2017; 30: 1–5. https://dx.doi.org/10.1093%2Fdote%2Fdow025
11. Pines G, Dickman R, Niv Y, Kashtan H, Birkenfeld S. Extraesophageal malignancies among patients with Barrett esophagus. J ClinGastroenterol. 2014; 48: e8–e11. https://doi.org/10.1097/MCG.0b013e31828bf26f
12. Sami SS, Dunagan KT, Johnson ML, Schleck CD, ShahND, ZinsmeisterAR et al. A randomized comparative effectiveness trial of novel endoscopic techniques and approaches for Barrett's esophagus screening in the community. Am J Gastroenterol. 2015; 110(1): 148-58. https://doi.org/10.1038/ajg.2014.362
13. Shaheen NJ, Falk GW, Iyer PG, GersonLB.AmericanCollege of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol 2016; 111(1): 30-50. https://doi.org/10.1038/ajg.2015.322
14. Solaymani-Dodaran M, Card TR, West J. Cause-specific mortality of people with Barrett’s esophagus compared with the general population: a population-based cohort study. Gastroenterology. 2013; 44(7): 1375-83. https://doi.org/10.1053/j.gastro.2013.02.050
15. Watanabe N, Shimizu M, Kochi T, Shirakami Y, Tanaka T. Esophageal carcinogenes. Op J Pathol. 2014; 4(4): 151-170. http://dx.doi.org/10.4236/ojpathology.2014.44021

Publication:

«World of Medicine and Biology» Vol. 16 No. 71 (2020) , с. 120-124
УДК 616.329-006.66-091.816

DOI:

https://doi.org/10.26724/2079-8334-2020-1-71-120-124